Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppressed HIV infection: A randomized open-label superiority trial. The AVERTAS-1 trial - AVERTAS-1

Department of infectious diseases, Hvidovre Hospital0 个研究点目标入组 95 人开始时间: 2020年2月14日最近更新: 2023年12月12日

试验速览

暂无简介。

•- Individuals = 18 years old with
•- Diagnosed HIV and
•- At least 6 months of ongoing treatment with dolutegravir/ abacavir/lamivudine prior to inclusion
•- No pre-existing viral resistance mutations to lamivudine or to dolutegravir
•- Plasma viral load (HIV-RNA) < 50 copies/ml
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 80
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•- Pre-existing viral resistance mutations to lamivudine or to dolutegravir
•- Presence of hepatitis B antigen (HBsAg) or HBV DNA
•- Cancer within past 5 years
•- Pregnancy or breastfeeding
•- Any case of diabetes or cardiovascular disease must be stable as assessed by the treating physician
•- Women of reproductive potential will be included if using approved contraception

发起方

Department of infectious diseases, Hvidovre Hospital